Metrics as of 10/17/2026, 06:24 AM (Berlin time), refresh in progress.
Humacyte Stock
Humacyte, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Laura E. Niklason
- Employees
- 184
- Market cap
- $119 M
- IPO
- 01/12/2020
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct…
Humacyte stock: price history
1D
-2.4%
1W
+5.8%
1M
-24.7%
6M
-39.6%
YTD
-55.3%
1Y
-74.8%
2Y
-92.6%
5Y
-95.8%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~54% stronger price swings than usual
Ask the agents about Humacyte
Analyst assessment of Humacyte
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.50
MEDIAN
US$1.50
PRICE TARGET HIGH
US$2.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 13/08/2026
Humacyte stock metrics
P/E
-0.84
P/B
3.21
EV/EBITDA
-1.33
RETURN ON EQUITY
-117.7%
NET MARGIN
-9,064.5%
DEBT/EQUITY
2.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.3%
FLOAT SHARES
250,790,573
AVG. DAILY VOLUME (30D)
5,416,930
Insider transactions (SEC)
Jones Keith Anthony
Jones Keith Anthony
Jones Keith Anthony
Sebelius Kathleen
Parikh Shamik J
Institutional holders
Comparable stocks
Frequently asked questions about Humacyte stock
What does Humacyte do?
Humacyte, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Laura E. Niklason, the company employs around 184 people.
The IPO was on 01/12/2020; the stock trades on NASDAQ under the ticker HUMA.
What do analysts say about Humacyte stock?
11 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
The average price target is US$1.50, ranging from US$1.00 to US$2.00, with a median of US$1.50.
This is an external assessment, not a statement by Market Jury.
When does Humacyte report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 54% stronger than usual.
Does Humacyte pay a dividend?
No, Humacyte currently does not pay a dividend.
Which stocks are comparable to Humacyte?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Humacyte stock analyzed?
Clicking "Analyze stock" lets five strategies assess Humacyte against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.